letrozole has been researched along with Astrocytoma, Grade IV in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 8.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "Letrozole has demonstrated efficacy in pre-clinical GBM models." | 5.62 | Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. ( Amarh, E; Assiri, AA; Dave, N; Overholser, BR; Pollok, KE; Shugg, T, 2021) |
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 4.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "Novel ruthenium-letrozole complexes have been prepared, and cell viability of two human cancer cell types (breast and glioblastoma) was determined." | 3.78 | New ruthenium(II)-letrozole complexes as anticancer therapeutics. ( Castonguay, A; Doucet, C; Juhas, M; Maysinger, D, 2012) |
| "Letrozole has demonstrated efficacy in pre-clinical GBM models." | 1.62 | Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. ( Amarh, E; Assiri, AA; Dave, N; Overholser, BR; Pollok, KE; Shugg, T, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karve, AS | 1 |
| Desai, JM | 1 |
| Dave, N | 2 |
| Wise-Draper, TM | 1 |
| Gudelsky, GA | 1 |
| Phoenix, TN | 1 |
| DasGupta, B | 1 |
| Sengupta, S | 1 |
| Plas, DR | 1 |
| Desai, PB | 1 |
| Shugg, T | 1 |
| Amarh, E | 1 |
| Assiri, AA | 1 |
| Pollok, KE | 1 |
| Overholser, BR | 1 |
| Tivnan, A | 1 |
| Heilinger, T | 1 |
| Ramsey, JM | 1 |
| O'Connor, G | 1 |
| Pokorny, JL | 1 |
| Sarkaria, JN | 1 |
| Stringer, BW | 1 |
| Day, BW | 1 |
| Boyd, AW | 1 |
| Kim, EL | 1 |
| Lode, HN | 1 |
| Cryan, SA | 1 |
| Prehn, JH | 1 |
| Castonguay, A | 1 |
| Doucet, C | 1 |
| Juhas, M | 1 |
| Maysinger, D | 1 |
4 other studies available for letrozole and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.
Topics: Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tumor; Drug Res | 2022 |
Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.
Topics: Androstadienes; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Ether-A-Go-Go P | 2021 |
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tum | 2017 |
New ruthenium(II)-letrozole complexes as anticancer therapeutics.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Aromatase Inhibitors; Autophagy; Breast Neoplasms; C | 2012 |